Prevention is the
Welcome to
Coming Soon
First-ever vaccine for systemic fungal infections in any species
Dangerous, debilitating fungal diseases affect millions of dogs every year. Just walking, playing, or digging outdoors puts dogs at risk.
Treatment requires months—and often a lifetime—of expensive antifungal therapies that carry the risk of side effects. Worse, early diagnosis is often missed, leading to delayed therapy, dissemination of the fungus throughout the body, and a poor prognosis.
New antifungal vaccines will soon replace 40-year-old treatment options
1st in class fungal vaccines
Canine Coccidioidomycosis
(CPS1 USDA)
In Development
Canine Blastomycosis
(BAD1 USDA)
In Development
Novel Vaccine Platform
Our new, never-done-before vaccine manufacturing process will bring groundbreaking preventive medicine to dogs across the US
Grow Spores
Avirulent fungal spores are grown on special plates that supply nutrients required to maximize growth
Transfer to Vials
Spores are transferred to vials containing the precise number of spores required to provide immunity
Lyophilization Process
Exposure to specific temperatures and pressures removes excess water to concentrate spores into a pellet
This novel production process will provide the blueprint for the manufacturing of multiple antifungal vaccines at scale
What used to be unpreventable will soon
have a vaccine
Valley Fever Vaccine
Anivive's Valley fever vaccine demonstrated efficacy in laboratory studies and now awaits completion of a field safety study prior to submission for approval.
The vaccine is designed to be given as an injection, the same way dogs receive other vaccines, with two injections the first year and a single booster annually.
All
Fungal
Oncology
Infectious
ALL PRODUCTS
FUNGAL
ONCOLOGY
INFECTIOUS
CANINE
Valley Fever
CPS1USDAIn Development
FELINE
FIP
INAD I-013287In Development
CANINE
Blastomycosis
BAD1USDAIn Development
CANINE
Hemangiosarcoma
INAD I-013225In Development
CANINE | FELINE
Gingivitis
Lysine DecarboxylaseIn Development
CANINE
Osteosarcoma
INAD I-013511In Development
Products in development not approved by the FDA or USDA